Mylan Shoots for Late 2013 Launch of Generic of Teva’s Copaxone

Despite analyst doubts, Mylan is confident it can launch a generic version of Teva’s blockbuster multiple sclerosis treatment Copaxone in the second half of 2013 pending FDA approval and resolution of legal challenges. Mylan expects a court decision “any day” on whether its ANDA impinges on Teva’s patents for the drug, CEO Heather Bresch said on a financial call.
Generic Line